Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
Vladimir Putin is sworn in for his fifth term as president at glittering ceremony in front of hand
Vladimir Putin has been sworn in for his fifth term as Russia's president in front of dignitaries, c2024-05-08Index reflects nation's strength in AI governance
China plays a leading role in the global development of artificial intelligence and has performed we2024-05-08China's mobile phone shipment tops 33 mln in January
A staff member displays a mobile phone screen film that can generate 3D vision with phone applicatio2024-05-08Tencent's AI technology to find pulsars 'FASTER'
(Global Times) 08:30, July 09, 2021The 500-meter aperture spherical radio telescope (FAST) sits in t2024-05-08Gone fishing... for some of New Zealand's trickiest trout: A stay at the world
The rotor blades are deafening as our chopper swoops down onto a rocky outcrop beside the Mokihinui2024-05-08Boeing ousts head of its 737 MAX program
Boeing announced Wednesday that it is removing the head of its 737 MAX passenger aircraft program fo2024-05-08
atest comment